Please cite this article as: Zoni, E., Karkampouna, S., Thalmann, G.N., Kruithof-de Julio, M., Spahn, M., Emerging aspects of microRNA interaction with TMPRSS2-ERG and endocrine therapy, Molecular and Cellular Endocrinology (2017), Abstract 1 Prostate cancer (PCa) is the most common malignancy detected in males and the second most 2 common cause of cancer death in western countries. The development of the prostate gland, is 3 finely regulated by androgens which modulate also its growth and function. Importantly, androgens 4 exert a major role in PCa formation and progression and one of the hypothesized mechanism 5 proposed has been linked to the chromosomal rearrangement of the androgen regulated gene 6 TMPRSS2 with ERG. Androgens have been therefore used as main target for therapies in the past. 7
18 Prostate cancer (PCa) is the second leading cause of death from cancer in males in western 19 countries, after lung cancer (Siegel et al. 2015) . The growth of the prostate is regulated by androgens 20 and the androgen dependency of prostate cancer has been established over half a century ago 21 (Huggins and Hodges 1941) . Despite the significant improvement in early cancer detection achieved 22 by PSA testing and in spite of the development of endocrine therapy (androgen ablation), when 23 prostate cancer progresses, tumors acquire resistance to this therapeutic castration and are 24 therefore classified as castration-resistant prostate cancer (CRPC) (Scher and Sawyers 2005) . 25
The notion that those prostate cancers arising during androgen deprivation therapy are androgen 26 independent has been reconsidered in the last years (Thompson et al. 2003) . Remarkably indeed, so 27 called "androgen independent" tumors often contain amplification of the gene encoding for the 28 androgen receptor (AR) (Visakorpi et al. 1995) and in many cases also overexpress the AR (Linja et al. 29 2001 , Chen et al. 2004 which is sufficient to switch the growth of PCa cells from androgen 30 dependence to androgen independence (Chen et al. 2004) . Multiple clinical trials have provided 31 evidence that CRPCs maintain androgen responsiveness (Tran et al. 2009 , Reid et al. 2010 . This 32 effect might be determined by metabolic alterations such as an activation of steroidogenic 33 pathways, potentially via a de novo intratumoral biosynthesis of steroid hormones, which might 34 facilitate tumor survival in presence of androgen deprivation therapy (ADT) (Green et al. 2012) . In 35 the past decade, one mechanism of androgens to induce PCa has been hypothesized to be due to 36 chromosomal rearrangement of the androgen regulated gene TMPRSS2 (transmembrane protease, 37 serine 2) and the ETS transcription factor ERG, which becomes also androgen regulated (Tomlins et 38 al. 2005) . This rearrangement usually occurs during cancer initiation and is also detected as early 39 event during tumor progression and is present in up to 50-60% of all prostate tumors (Visakorpi 40 2012) . In addition to the involvement of androgens and AR, which fundamentally drive PCa, 41 Glucocorticoids (GCs) are another class of steroidal hormones that recently have been shown to 42 mediate chemotherapy resistance (Kroon et al. 2016 ). This opened new possibilities for novel 43 therapeutic approaches, suggesting the application of GCs and Glucocorticoid Receptor (GR) 44 antagonism to re-sensitize resistance to taxane-based drugs in PCa (Kroon et al. 2016). 45 Endocrine therapy has been used for decades to treat prostate cancer and its complications. An 46 interesting aspect of the effect that this therapy can produce, is its influence on small noncoding 47 RNA (microRNAs, miRNAs, miRs). 48 microRNAs are evolutionary conserved short noncoding single-stranded RNA molecules 49 (approximately 18-22 nucleotides long) that regulates protein abundance (Ambros 2004). miRNAs 50 negatively regulate the translation of target mRNA by binding to their 3' untranslated region (UTR) 51
or, although to less extent, to their 5'UTR or coding sequence. In presence of perfect 52 complementarity between the seed sequence of the miRNA and the mRNA, this will result in mRNA 53 degradation; alternatively, if the binding is not perfect, it will produce translational repression 54 (Valinezhad Orang et al. 2014) . microRNAs regulate a vast variety of processes, such as cell 55 proliferation, motility, apoptosis, maintenance of stem-like properties and have been implicated in 56 PCa initiation, progression and metastases. 57
Each miRNA can modulate the expression of multiple mRNAs and a single mRNA can be modulated 58 by multiple miRNAs, leading to a biological complexity which makes miRNAs important regulators of 59 many properties of normal and neoplastic cells. Depending on the mRNA target genes, miRNAs are 60 classified in tumor suppressor miRs or onco-miRs and their expression can be aberrant in cancerous 61 cells. miRNAs represent a relatively recent class of interesting molecules of potential utility as PCa 62 biomarkers, beside the employment of proteins and mRNA measurement in the clinical practice. 63
This also opens new possibilities for the use of miRNAs as predictive markers for endocrine therapy 64 response. 65
In this review, we focus on the interactions between microRNAs and endocrine-related aspects of 66 Prostate Cancer   72  73 Deregulations of microRNAs, through processes such as promoter methylation, histone 74 modifications, genomic deletion and upstream protein alteration (Lujambio et al. 2008 , Shi et al. 75 2008 , have been documented in multiple cancers (Lu et al. 2005 , Volinia et al. 2006 . A significant 76 portion of microRNAs are indeed localized in the proximity of CpG islands, which are susceptible 77 sites of epigenetic silencing (Rauhala et al. 2010) . A pattern of microRNA downregulation has indeed 78 been documented for multiple malignancies such as colorectal (Michael et al. 2003 , Cummins et al. 79 2006 and lung cancer (Yanaihara et al. 2006 ) and has also been suggested to reflect the lower 80 differentiation stage of the tumor cells compared with normal cells (Lu et al. 2005 , Porkka et al. 81 2007 . Together, this supports the general pattern of downregulation that has been described in 82 prostate cancer in microRNA expression studies comparing benign vs. cancerous tissues (Porkka et 83 al. 2007 , Ozen et al. 2008 , Spahn et al. 2010 . 84 A comprehensive review by Fabris et al., has recently summarized the microRNAs that are 85 consistently altered in PCa tissues in different studies and associated with the same trend of 86 expression (Fabris et al. 2016 ). Among the most common microRNAs consistently downregulated in 87 PCa tissues, miR-125b, miR-145 and Let-7b are associated with altered apoptosis (Porkka et al. 2007 , 88 Ambs et al. 2008 , Ozen et al. 2008 , Martens-Uzunova et al. 2012 , Larne et al. 2013 , miR-205 with 89 cell proliferation (Porkka et al. 2007 , Ambs et al. 2008 ) and miR-221 and miR-222 with cell cycle 90 (Porkka et al. 2007 , Ambs et al. 2008 , Martens-Uzunova et al. 2012 , Larne et al. 2013 ). On the other 91 hand, among the most common microRNAs consistently upregulated in PCa tissues, miR-93 is 92 associated with metastasis and miR-25 with cell proliferation (Volinia et al. 2006 , Martens-Uzunova 93 et al. 2012 . Despite the large volume of information generated with expression analysis of bulk-94 tissues, it is becoming increasingly evident that such approaches also reduce the chances of 95 measuring the contribution of microRNAs altered in specific subpopulation of cells (e.g. cancer 96 progenitor/stem-like cells). Studies focused on microRNA alterations in selected metastatic Prostate 97 Cancer Stem Cells (CSCs) have shown, for example, that a microRNA (miR-25) previously shown to be 98 increased in PCa "bulk tissues" (Volinia et al. 2006 ) was significantly downregulated in PCa CSCs and 99 restored expression of miR-25 resulted in strong reduction of distant growth of PCa cells inoculated 100 in zebrafish embryos . Despite big progresses in the development of new drug delivery strategies, the applicability of 106 miRNAs as therapeutic agents is still in its infancy. This is mainly due to multiple challenges such as 107 specificity and therapeutic delivery (Conde and Artzi 2015). Moreover, the observation of decreased 108 microRNAs during cancer formation and progression, has led to the concept of microRNA 109 replacement therapy. An example of this was recently described with the AR regulating miR-34a 110 (Ostling et al. 2011) : it was shown that nanoparticle-mediated delivery of miR-34a decreased PCa 111 cells growth in the bone (Gaur et al. 2015) . However, microRNAs may have clear diagnostic and 112 prognostic value and can be employed as predictors of therapy response and biomarkers (Junker et 113 al. 2016). 114 Interestingly, although endocrine therapy has been used for decades, its influence on the expression 115 of microRNAs in clinical tissue specimens has not been extensively analyzed (Lehmusvaara et al. 116 2013) . In a recent study (Lehmusvaara et al. 2013 ), the expression of 723 human microRNAs was 117 analyzed in freshly frozen specimens from PCa patients treated with goserelin and bicalutamide vs. 118 untreated controls (Lehmusvaara et al. 2012) . In this study, a significant difference in microRNAs 119 modulation was registered upon the treatments. Among the 19 miRNAs with decreased expression, 120 six were common to both treatments, namely miR -9, miR-492, miR-210, miR-149, miR-200a and 121 miR-200b (Table I) . Conversely, among the 23 miRNAs with increased expression, only three were 122 common to both treatments, namely miR-99a, miR-125b and miR-100 (Table I) . Strikingly, the 123 majority of the microRNAs measured in this study, displayed a pattern of upregulation upon 124 treatment. Given that the expression of microRNAs has been shown to be reduced during PCa 125 progression (Lu et al. 2005 , Martens-Uzunova et al. 2012 , this suggests that, the registered pattern 126 of expression upon treatment, might indicate a therapeutic response and a reduction of cancerous 127 characteristics (Lehmusvaara et al. 2013) . It is important to note that, the two treatments 128 investigated in the study, differ significantly for the targeting mechanism: goserelin affects the 129 androgen production from the testis whereas bicalutamide prevents DHT binding to the AR. Given 130
therapeutic approaches targeting multiple pathways (e.g. ERG and AR) might be promising to 139 improve patient's response. 140
On the other hand, miR-99a and miR-100 displayed an increase upon bicalutamide and goserelin 141 treatment. Innterestingly, inhibition of the GR by mifepristone (Lin et al. 1995) resulted in an 142 enhanced miR-99a/100-mediated radiation response in patient-derived prostate cells (Rane et al. 143 2016) . This support the notion that, targeting AR and GR pathway simultaneously, might represent a 144 strategy to prevent resistance to chemotherapy in a later stage of the disease. 145
Morevoer, in a miRNA library screening to identify anti-androgen bicalutamide PCa resistance-146 related microRNAs, miR-216a was identified as associated with endocrine resistance (Miyazaki et al. 147 2015) . Ectopic expression of miR-216a inhibited bicalutamide-mediated growth suppression of 148
LNCaP cells and miR-216a was upregulated upon DHT treatment. This suggests that miR-216a might 149 be employed as marker to monitor endocrine therapy response in PCa. 150
Another approach to target endocrine signaling in PCa, is to interfere with AR coactivators (Culig and 151 Santer 2013) . The transcriptional integrator p300 and its functional homologue CBP, have been 152
shown to be involved in AR transactivation and to display acquisition of agonistic properties of 153 hydroxyflutamide, a non-steroidal antiandrogen. Moreover, androgen ablation therapy resulted in 154 increased expression of p300 and CBP (Debes et al. 2003 , Comuzzi et al. 2004 , Heemers et al. 2007 . 155
Inhibition of p300 and CBP by a newly developed molecule C646 (Bowers et al. 2010 ) (p300 histone 156 acetyltransferase inhibitor) in androgen-sensitive and -insensitive cell lines reduced proliferation 157 and invasion (Santer et al. 2011) . Recently, we identified in silico a signature of 30 validated 158 microRNAs associated with p300/CBP in the context of EMT in cancer . Strikingly, 159 multiple microRNAs identified in our signature appear to be relevant for their involvement in 160 endocrine aspects in PCa. 161
The previously discussed miR-9 was one of the 30 miRs identified in our signature and was shown to 162 target p300 (Grimson et al. 2007) . Moreover, in a screening of 1129 miRNAs to identify microRNAs 163 regulating the AR at protein level, miR-9 was identified as direct targets the 3'-UTR of AR (Ostling et 164 al. 2011 ). This reinforce the identification of miR-9 as a promising marker for endocrine therapy 165 response in PCa. Additionally, in the same study, miR-135b, miR-185, miR-297, miR-299-3p, miR-34a, 166 miR-34c, miR-371-3p, miR-421, miR-449a, miR-449b, miR-634 and miR-654-5p were identified as 167 direct binding partners of the 3'UTR of AR (Ostling et al. 2011) . The assessment of the levels of these 168 microRNAs, could therefore represent a promising measurement to address the microRNAs 169 response upon endocrine therapy. Furthermore, miR-26b, miR-182 and miR-200b were also 170 previously reported to interact with p300/CBP (Mees et al. 2010) . These three miRs are associated 171 with ERG modulation, TMPRSS2-ERG correlation and endocrine treatment respectively. Together GCs are steroidal hormones that have been used in the treatment of prostate cancer, typically in 183 combination with docetaxel and abiraterone acetate in the castration-resistant phase of the disease, 184 reviewed in (Montgomery et al. 2014) . The rationale for the administration of GCs is basically related 185 to slow disease progression, improve pain control and reduce the side effects of chemotherapy 186 (Piccart et al. 1997 , Attard et al. 2012 . GCs can suppress androgen synthesis through inhibition of 187 the hypothalamic/pituitary axis, which results in suppression of testicular and adrenal androgen 188 production (Alesci et al. 2001 ). However, GCs usage remains controversial as both pro-and 189 antitumor effects have been documented (Montgomery et al. 2014) . Additionally, GR expression is 190 enhanced in PCa patients who received docetaxel and in docetaxel-resistant cell lines (Kroon et al. 191 2016) . Moreover, GR antagonism by RU-486 and cyproterone acetate (CPA), has been shown to 192 revert docetaxel resistance in human PCa, opening new possibilities for the clinical utility of the GR 193 antagonists in the management of patients with advanced PCa (Kroon et al. 2016). 194 To date, only one report has highlighted the functional connection between miRs and GR in the 195 context of human prostate cancer (Rane et al. 2016) . Rane et al., have shown that inhibition of the 196 GR by mifepristone (Lin et al. 1995) results in an enhanced miR-99a/100 expression (Table I) and 197 increased radiation response in patient-derived prostate cells (Rane et al. 2016). miR-99a and miR-198 100 have been shown to be significantly suppressed in prostate stem-like cells (CD133 + , α 2 β 1 hi cells) 199 compared to their differentiated progeny committed basal cells (CD133 − , α 2 β 1 lo ) (Rane et al. 2015) . 200 CD133 + cells have been reported to be tumorigenic in vivo after fractionation of heterogeneous bulk 201 samples (Maitland et al. 2011) . Strikingly, the similar pattern of downregulation in microRNA 202 expression during PCa progression, documented in a remarkable number of studies, is also observed 203
in tumorigenic prostate cancer stem-like cells vs. more differentiated cells (i.e. miR-99a and miR-100 204 are decreased in prostate stem-like cells vs. committed basal cells). Thus, during progression 205 towards a more aggressive state, there seems to be a general tendency to reduce the expression 206 levels of tumor suppressor microRNAs. 207
Interestingly, TMPRSS2-ERG has been reported to be expressed in the stem-like compartment 208 (CD133 + , α 2 β 1 hi cells) enriched for CD44 + cells (Birnie et al. 2008) . Together, this suggest that miR-209 99a/100 present in fusion-positive prostate cancer stem-like cells might represent interesting target 210 molecules in combination with endocrine-therapy aimed to inhibit GR. 211 212 213 microRNA interactions with TMPRSS2-ERG 214 215
The chromosomal rearrangement resulting in the formation of the fusion gene between TMPRSS2 216 and the transcription factor ERG, is detected in approximately 6% of benign prostatic hyperplasia 217 (BPH) and 50 -60% of all PCa (Tomlins et al. 2005 , Clark et al. 2007 . It was reported 218 that the frequency of the TMPRSS2-ERG fusions in high-grade PIN lesions and localized PCa, is about 219 15% and 50% respectively (Clark et al. 2008 , Mosquera et al. 2008 ), suggesting that this event either 220 occurs after cancer initiation, or alternatively predisposes to clinical progression Shen 2010), althought this is not cancer restricted. It has also been proposed that the formation of 222 this chromosomal rearrangement might be controlled by androgens; AR binding in LNCaP androgen 223 responsive PCa cells resulted in juxtaposition between the AR regulated promoter of TMPRSS2 and 224 ERG (Lin et al. 2009 ). Moreover, androgen signaling might recruit topoisomerase II inducing double 225 strand breaks even in absence of stress (Haffner et al. 2010 , Kolar et al. 2014 Although extensive research, (reviewed in (Tomlins et al. 2009 , Adamo and 227 Ladomery 2016 , Archer et al. 2016 ) has been performed in the last years, related to ERG-induced 228 oncogenesis in PCa, following the chromosomal rearrangements with TMPRSS2, only few studies 229 have functionally investigated the reciprocal influences between microRNAs and TMPRSS2-ERG 230 fusion gene. 231 miR-221 is one of the microRNAs that was shown to be progressively downregulated in aggressive 232 prostate cancer in hormone naïve tumors and it has been proposed as novel prognostic biomarker 233 and therapeutic target in high-risk prostate cancer, being an effective predictor of clinical recurrence 234 (Spahn et al. 2010) . Recently, miR-221 was shown to regulate prostate cancer cell growth, 235 invasiveness, and apoptosis via direct inhibition of SOCS3 and IRF2, two oncogenes that negatively 236 regulate the JAK/STAT signaling pathway (Kneitz et al. 2014) (Fig. 1) . Interestingly, Gordanpour et al., 237 have shown that miR-221 is downregulated in prostatic tumors bearing TMPRSS2-ERG fusion M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT 10 transcripts (Table II) (Gordanpour et al. 2011) , providing the first published evidence for miRNA 239 associations in prostate cancer that overexpress the ERG oncogene from the TMPRSS2-ERG fusion 240 transcript. However, it is important to highlight that in PCa the situation seems to be more complex, 241 because Sun et al. (Sun et al. 2014) , have shown that miR-221 expression levels are increased in 242 tissue derived from bone metastasis of CRPC, which suggests a specific function of miR-221 in the 243 development of androgen resistance. miR-221 could indeed abolish proliferation in the SOCS3-244 positive and androgen independent PC3 and Du145, but not in the SOCS3-negative and androgen 245 dependent LNCaP cells (Kneitz et al. 2014) . Together this supports the notion that in PCa the 246 sensitivity against androgen signaling depends on SOCS3 expression (Neuwirt et al. 2007 ) and that 247 miR-221 might play a pivotal role in the regulation of the androgen-independent growth. 248
Remarkably, the mechanism of pathogenesis for fusion-negative tumors compared to TMPRSS2-249 ERG positive ones, is still not entirely elucidated (Borno et al. 2012) . Interestingly, distinct epigenetic 250 mechanisms distinguish TMPRSS2-ERG fusion-positive and -negative prostate cancers (Alumkal and 251 Herman 2012) and, as previously discussed, DNA methylation and histone modifications are two 252 epigenetic mechanisms responsible for the de-regulation of microRNAs expression (Lujambio et al. 253 2008) . Interestingly, one of the highly upregulated genes during prostate cancer progression is the 254 human homologue of the Drosophila protein Enhancer of Zeste 2 (EZH2), which belongs to the group 255 of polycomb proteins and is involved in silencing of homeobox genes through methylation (Pirrotta 256 1998 , Hoffmann et al. 2007 . 257 EZH2 is a target of the TMPRSS2-ERG gene fusion, and TMPRSS2-ERG and EZH2 cooperate in the 258 regulation of shared target genes, including AR (Yu et al. 2010) . Aberrant DNA methylation 259 associated with altered EZH2 expression correlates with PCa progression and has been proposed as 260 an early event in tumorigenesis (Varambally et al. 2002) . Interestingly, a recent report has 261 documented the global epigenetic alterations in fusion-negative tumors, providing a mechanistic 262 explanation for the formation of these cancers (Borno et al. 2012) . In this report, it has been 263 proposed that hypermethylation of miR-26a is an alternative way to activate EZH2 in an ERG 264 rearrangement-independent manner. miR-26a directly targets EZH2 and it is suppressed in fusion-265 negative prostate cancers (Table II, Fig. 1) (Borno et al. 2012) . This suggests that a suppression of 266 miR-26a caused by a hypermethylation leads to a decreased inhibition of EZH2, leading to 267 perturbations to the global DNA methylation profile, providing a new mechanistic model for fusion-268 negative tumors (Borno et al. 2012). 269 Given the established notion that ERG is overexpressed in a high proportion of the prostate 270 carcinomas (Tomlins et al. 2005 (Hagglof et al. 2014) and is accompanied by loss of E-cadherin expression, increased cell 274 mobility and invasion (Leshem et al. 2011) . Additionally, is has been proposed that TMPRSS2-ERG 275 promotes epithelial-to-mesenchymal transition (EMT) through the ZEB1/ZEB2 axis in PCa (Leshem et 276 al. 2011 ). Interestingly, it was recently shown that docetaxel resistant human PCa cells display EMT 277 features and properties of tumor-initiating cells (Puhr et al. 2012 ) and experimental work revealed 278 that these cells display upregulation of ZEB1 and downregulation of has been recently identified as downstream target of ERG and miR-200c expression in tissues from 280 patients with ERG-positive PCa was significantly lower compared with ERG-negative tumors ( Table  281 II), supporting the notion that ERG directly represses miR-200c (Kim et al. 2014) . These data together 282 indicate that ERG might be involved in the acquisition of chemotherapy resistance and suggest that 283 monitoring of ERG, miR-200c and ZEB1 in PCa patient's tissues might be relevant to predict the 284 outcome of chemotherapy (Culig 2014) (Fig. 1) . 285
Another microRNA relevant in the context of EMT and TMPRSS2-ERG positive tumors is miR-30 (Kao 286 et al. 2014 ). Kao et al, have demonstrated that ERG is a direct target of miR-30 and increased 287 expression of miR-30 in VCaP and PC3 prostate cancer cells resulted in reduction of EMT phenotypes 288 and abolished migration and invasion (Kao et al. 2014) (Fig. 1) . miR-30 has been shown to be 289 significantly downregulated in tumor vs. benign tissue and in hormone-refractory prostate cancer 290 (Porkka et al. 2007) . Interestingly, administration of selective inhibitors of Src-family tyrosine kinases 291 resulted in a strong upregulation of miR-30 and decreased ERG expression at mRNA and protein 292 level. Given that specific Src kinase inhibitors have been tested in Phase I, II and III clinical trials (in 293 combination with docetaxel (Araujo et al. 2013) ) for the treatment of PCa patients, this suggests the 294 employment of Src inhibitors for especially targeting ERG-positive castration-resistant tumors. 295
However, the role of EMT in the context of androgens and androgen-regulated genes seems to be 296 more complex: AR splice variants appears to contribute to PCa aggressiveness and EMT induction 297 (Kong et al. 2015) , however ADT has been shown to generate EMT in normal and neoplastic prostate 298 in animal models (Sun et al. 2012) . 299 miR-145 is a direct regulator of ERG and shown to be consistently downregulated in prostate cancer 300 (Hart et al. 2013) . Although no association between miR-145 and ERG mRNA expression is reported, 301 a negative correlation between miR-145 and ERG protein was demonstrated (Table II) (Hart et al. 302 2013) . Interestingly, the documented reduction of miR-145 in PCa might support the elevated 303 expression of multiple ERG isoforms, all detected ERG variants display, indeed, the miR-145-304 responsive 3′ UTR seed sequence (Hart et al. 2013) (Fig. 1) .
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12 Finally, miR-187 also displayed a strong pattern of downregulation during PCa progression in a 306 cohort of 50 PCa samples vs. 10 normal tissues (Casanova-Salas et al. 2014 ). These results were 307 validated in an independent cohort of 273 paraffin embedded PCa samples and displayed an inverse 308 correlated with TMPRSS2-ERG expression (Table II) (Casanova-Salas et al. 2014) . Notably, in the 309 same study, a positive correlation between miR-182 and TMPRSS2-ERG was detected and miR-182 310 was shown to be significantly associated with progression free survival and revealed to be a 311 significant independent predictor of worse outcome for biochemical progression free survival 312 (defined as PSA 0.4 ng/ml or greater during follow-up) but not for progression free survival (defined 313 as local, lymph nodes or distant metastasis growth) (Casanova-Salas et al. 2014) . Therefore, miR-187 314 and miR-182 have been proposed as biomarkers of early diagnosis and prognosis in PCa patients 315 ( Fig. 1) . Interestingly, miR-182 has been shown to be directly regulated by the AR and to promote 316 prostate cancer cell proliferation, invasion and migration and inhibit apoptosis (Yao et al. 2016) . 317 Accordingly, miR-182 expression is increased in AR-positive cell lines, such as LNCaP, 22RV1 and C4-318 2, and reduced in the AR-negative cell line DU145 (Yao et al. 2016 As previously discussed, ERG has been extensively shown to be implicated in PCa initiation and 327 progression and to be involved in multiple processes such as EMT, invasion and metastasis. ERG 328 based therapy options have been recently comprehensively reviewed by Adamo et al. (Adamo and Poly(ADP-Ribose) Polymerase (PARP) is a DNA repair protein which interacts with ERG through a 332 DNA-independent mechanism (Sebastian de Bono et al. 2011) . Inhibition of PARP reduces the 333 aggressiveness of ERG-positive PCa cells. High levels of miR-182 in breast cancer increased the 334 sensitivity to PARP1 inhibitors and antagonizing of miR-182 resulted in the opposite effect (Moskwa 335 et al. 2011) . Given the increased levels of miR-182 in AR and TMPRSS2-ERG positive cells (Casanova-336 Salas et al. 2014) , this reinforces the use of PARP1 inhibitors to target ERG-positive PCa cells. 337
Administration of PARP inhibitor, rucaparib, to ERG-positive and PTEN-negative PCa cells sensitized 338 the cells to low-dose radiation which possibly generate DNA DSB (Chatterjee et al. 2013). 339 Interestingly, two mechanisms for PARP inhibition have been proposed: 1) inhibition of the PARP1-340 ETS complex, a key component for the ERG-mediated invasion and cell growth; 2) lethality following 341 the accumulation of DNA DSB (Brenner et al. 2011 ), which supports the described effect with 342 radiations. Interestingly, gain-of function screen of 1129 miRNAs in a panel of human PCa cell lines, 343
identified and validated miR-9 as direct regulator of AR in PCa (Ostling et al. 2011) . Moreover, in 344 ovarian cancer, miR-9 was shown to increase cellular sensitivity to the same PARP1 inhibitor (Sun et 345 al. 2013) . In another report, Nowek et al. demonstrated that miR-9 directly targets ERG (Nowek et al. 346 2016) . Together this suggest that miR-9 might exerts a synergistic effect with ERG-targeted therapy 347 in human PCa. miR-9 was also moderately upregulated in a panel PCa cell lines upon administration 348 of trichostatin A (TSA), and HDAC inhibitor, which reduces growth of ERG-positive PCa cells and 349 deceases the expression of TMPRSS2-ERG (Table I) (Rauhala et al. 2010) . However, in the same study, 350 miR-193 displayed a significantly higher induction upon TSA treatment and was shown to be 351 downregulated in PCa samples vs. BPH, suggesting a tumor suppressive role for this microRNA (Table  352 I) (Rauhala et al. 2010) . Another microRNA interesting for its pattern of expression during disease 353 progression is miR-1296. This microRNA is downregulated in PCa tissues compared to BPH and 354 directly targets the minichromosome maintenance gene 2 (MCM2) (Majid et al. 2010) . MCM2 is 355 involved in DNA replication, is upregulated in PCa and correlates with poor survival (Meng et al. 356 2001 , Majid et al. 2010 . Interestingly, TSA treatment in PCa cell lines PC3 and LNCaP cell resulted in 357 decreased MCM2 protein expression (Majid et al. 2010 ), suggesting that miR-1296 might represent 358 another molecule with synergistic properties to reduce growth of ERG-positive PCa cells. 359
Finally another strategy for ERG-based therapy is its direct targeting with molecules promoting 360 degradation. USP9X is a ubiquitin-specific peptidase which stabilizes ERG and knockdown of USPX9 361 resulted in increased ERG degradation, following ubiquitination (Adamo and Ladomery 2016) . 362
Inhibition of USP9X with direct inhibitor WP1130, resulted in in ERG degradation and inhibited M A N U S C R I P T
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14 growth of ERG-positive tumors in vivo (Wang et al. 2014) . Interestingly, miR-26b has been shown to 364 directly target USP9X (Shen et al. 2014 ) and is markedly downregulated in PCa tissues (Kato et al. 365 2016) . This suggests that miR-26b replacement therapy might inhibit USP9XP, leading to ERG 366 degradation and inhibition of ERG-positive PCa. Given the positive outcome of preclinical studies 367 which employed non-toxic liposomal nanovectors to selectively knockdown TMPRSS2-ERG fusion 368 (Shao et al. 2012) , this opens new scenarios for microRNA replacement therapies and for the delivery 369 in situ of miRNA mimics capable of interfering with ERG signaling, in combination with ERG-targeted 370 therapy. 371 372 373 Conclusion and perspectives: 374 375 In this review, we discussed and summarized the interactions between microRNAs and endocrine-376 related aspects of prostate cancer. We discussed multiple aspects of androgen-and glucocorticoid-377 targeted therapy and the influences of these treatments on the modulation of microRNA expression. 378
We specifically highlighted the different approaches to investigate the connections between 379 microRNAs and the androgen-regulated gene TMPRSS2-ERG and also discussed novel insights into 380 the effect of GR targeting in advanced prostate cancer and microRNAs. 381
The diagnostic and prognostic value of microRNAs is nowadays clear. Non-coding RNAs can be 382 employed as biomarkers and predictors of therapy response. However, the applicability of miRs as 383 therapeutic agents in oncology is still in its developmental phase, mainly due to therapeutic delivery 384 challenges. The intrinsic a-specificity that microRNAs present is one of the biggest challenge in the 385 achievement of anti-tumor response with acceptable side effects. Additionally, the 386 microenvironment and tissue dependent "dual" function of microRNAs as tumor suppressors or 387 oncogenes is one of the main challenges for a therapeutic approach. 388
We believe that miRNA targeted therapy will be attempt, once that a selective therapeutic delivery 389 system will be developed to specifically target cancerous cells. Meanwhile, the employment of 390 microRNAs as predictors of therapeutic outcome is one of the strategies for better patient 391 stratification and treatment response in the perspective of a personalized medicine era. 1) Endocrine therapy modulates microRNA expression 2) miR-221 is downregulated in TMPRSS2-ERG tumors 3) miR-9 might act synergistically with ERG-targeted therapy in human PCa 4) miR-200c has been identified as downstream target of ERG 5) miR-99a/100 have been shown to be enhanced upon GR inhibition in PCa
